Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NKG2-C type II integral membrane protein, encoded by the KLRC2 gene, is an activating receptor primarily expressed on natural killer (NK) cells and subsets of cytotoxic T cells. It forms a disulfide-linked heterodimer with CD94 (KLRD1) and associates with the immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor protein DAP12 (TYROBP) to transduce activating signals. The CD94/NKG2C complex specifically recognizes HLA-E, a non-classical MHC class I molecule, presenting peptides derived from other MHC class I molecules or viral proteins. This interaction triggers NK cell degranulation, cytokine production, and proliferation, playing a critical role in antiviral defense—particularly against human cytomegalovirus (HCMV)—and tumor immunosurveillance.
In therapeutic development, KLRC2 is a highly promising target for cancer immunotherapy and adoptive cell therapies. NKG2C-expressing 'adaptive' or 'memory-like' NK cells are being expanded ex vivo using agonist antibodies or utilized in allogeneic cell therapies (such as IDP-023) to target HLA-E-expressing tumors. Additionally, novel bispecific and dual-targeting antibodies, such as ES015, are designed to simultaneously block the inhibitory NKG2A receptor and activate NKG2C to maximize antitumor efficacy. However, therapeutic challenges include potential NK cell exhaustion under chronic stimulation and the fact that a small percentage of the human population carries a homozygous deletion of the KLRC2 gene, rendering NKG2C-targeted therapies ineffective in these individuals.
NKG2C targeting drugs act primarily through receptor activation (agonism) to trigger NK cell cytotoxicity and cytokine release. This is achieved via agonist monoclonal antibodies, dual-acting antibodies (which simultaneously block inhibitory NKG2A and activate NKG2C), multispecific killer cell engagers (such as TriKEs) that redirect NK cells to tumor antigens, or adoptive cell therapies utilizing expanded NKG2C-positive adaptive NK cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NKG2-C type II integral membrane protein (NKG2C) (NKG2C).